版本:
中国

BRIEF-Aimmune completes and exceeds North American enrollment target

Sept 20 Aimmune Therapeutics Inc :

* Aimmune Therapeutics completes and exceeds North American enrollment target ahead of schedule in phase 3 palisade trial of AR101 for treatment of peanut allergy

* Says New Ramses real-world experience study to begin in 1Q 2017 Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐